β2 adrenergic receptor agon 
Welcome,         Profile    Billing    Logout  
 47 Companies  88 Products   88 Products   263 Diseases   185 Trials   10041 News 


12345678910111213...2526»
  • ||||||||||  Airsupra (budesonide/salbutamol) / AstraZeneca, Avillion
    Journal:  The use of albuterol/budesonide as reliever therapy to reduce asthma exacerbations. (Pubmed Central) -  Apr 9, 2024   
    This combination approach, shown to decrease asthma exacerbations and oral corticosteroid burden in patients with moderate-to-severe asthma, represents a paradigm shift for asthma treatment in the US. Further safety and efficacy studies should provide evidence that this type of reliever should be standard of care.
  • ||||||||||  Fasenra (benralizumab) / AstraZeneca
    Journal:  Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia. (Pubmed Central) -  Apr 3, 2024   
    P3
    Subsequent studies, particularly those focusing on implementation, should explore the potential integration of the app into standard treatment practices. MIRACLE data reinforces the efficacy and safety of benralizumab for severe eosinophilic asthma in an Asian population, consistent with the global Phase 3 results.
  • ||||||||||  Neutrophil specific glycogen metabolism supports antifungal function in the infected tissues (Exhibit Hall F1; Posterboard Number: 661) -  Mar 29, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_1752;    
    Finally, treatment with ?2-adrenergic receptor agonist, an approved drug and activator of PYGL function, improved antifungal activities of neutrophils in candidiasis. These results provide insights on how glycogenolysis supports compensatory metabolic reprograming required for antifungal function of neutrophils in the glucose-depleted infected tissues, a knowledge that can be therapeutically exploited by an approved drug.
  • ||||||||||  Neutrophil specific glycogen metabolism supports antifungal function in the infected tissues (Room W176) -  Mar 22, 2024 - Abstract #IMMUNOLOGY2024IMMUNOLOGY_291;    
    Finally, treatment with ?2-adrenergic receptor agonist, an approved drug and activator of PYGL function, improved antifungal activities of neutrophils in candidiasis. These results provide insights on how glycogenolysis supports compensatory metabolic reprograming required for antifungal function of neutrophils in the glucose-depleted infected tissues, a knowledge that can be therapeutically exploited by an approved drug.
  • ||||||||||  Curosurf (poractant alfa) / Chiesi, Onbrez (indacaterol) / Novartis
    Journal:  Evaluating ?2-agonists as siRNA delivery adjuvants for pulmonary surfactant-coated nanogel inhalation therapy. (Pubmed Central) -  Mar 19, 2024   
    As opposed to the least hydrophobic drugs salbutamol and formoterol, the more hydrophobic long-acting ?2-agonist (LABA) salmeterol promoted siRNA delivery in both cell types for both uncoated and surfactant-coated nanogels, whereas indacaterol showed this effect solely in lung epithelial cells. Our results demonstrate the potential of both salmeterol and indacaterol to be repurposed as adjuvants for nanocarrier-mediated siRNA delivery to the lung, which could provide opportunities for drug combination therapy.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron
    Efficacy and Safety of Dupilumab in Patients With Moderate-to-Severe COPD and Type 2 Inflammation: Phase 3 NOTUS Trial (Marriott Marquis San Diego Marina, Grand Ballroom 11-13 (Lobby Level, North Tower)) -  Mar 17, 2024 - Abstract #ATS2024ATS_8456;    
    P3
    Dupilumab is the first biologic to significantly reduce moderate-severe exacerbations and improve lung function in patients with COPD and type 2 inflammation in two phase 3 trials. Dupilumab was well tolerated, and the safety profile is generally consistent with other dupilumab indications.
  • ||||||||||  Veltassa (patiromer) / , Lokelma (sodium zirconium cyclosilicate) / AstraZeneca
    Review, Journal:  Hyperkalemia: Pharmacotherapies and Clinical Considerations. (Pubmed Central) -  Feb 26, 2024   
    Each of these medications has unique benefits and contraindications. Clinicians must be aware of these medications when managing patients with hyperkalemia.
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    Journal, Real-world evidence, Real-world:  Real-world users of triple therapy for asthma in the US. (Pubmed Central) -  Feb 25, 2024   
    In real-world practice, triple therapy is often utilized following other asthma controller medication use. High disease burden, as evidenced by substantial use of rescue medications and continued asthma-related exacerbations, suggests that patients may not have achieved adequate asthma control prior to triple-therapy initiation.
  • ||||||||||  Journal:  The Impact of Australian Bushfires on Asthma Medicine Prescription Dispensing. (Pubmed Central) -  Feb 23, 2024   
    According to significant improvements in CAT and SGRQ score, LAMA may be preferred over LABA as a bronchodilator agent in group A COPD patients, especially in emphysema-dominant phenotype. The increase in the number of dispensed asthma prescriptions during the bushfire season should be used to inform the stock holdings of these medicines in preparation for future events to ensure access to lifesaving asthma medicines.
  • ||||||||||  aspirin / Generic mfg.
    Biomarker, Journal, Real-world evidence, Real-world:  Diagnostic biomarkers for chronic rhinosinusitis in adult asthmatics in real-world practice. (Pubmed Central) -  Feb 21, 2024   
    Patients with COPD treated with ICS/LABA during baseline, including patients specifically treated with BUD/FORM and those with a history of ??1 exacerbation, had fewer COPD exacerbations and lower COPD-related HCRU after initiating FF/UMEC/VI. The CRS group had higher blood eosinophil counts/FeNO levels and prevalence of aspirin-exacerbated respiratory disease (AERD) than the non-CRS group (n
  • ||||||||||  Uncovering Acute Exacerbations Via Reliever Use Patterns Using Digihaler Inhaler Data (San Diego Convention Center, Room 28C-E (Upper Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_7232;    
    Both threshold rules used in this analysis were considered very conservative, as they far exceed the upper limit of weekly SABA use suggested by guidelines. Despite using extremely conservative definitions of SABA overuse as proxy measures for exacerbations, we identified an unacceptably high incidence of likely asthma exacerbations (1.61/participant), of which the overwhelming majority were not recognized by the participants or HCPs.Objective SABA usage data from the Digihaler inhaler may help detect asthma exacerbations that would otherwise not be identified as such by asthma patients or HCPs.
  • ||||||||||  Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH): An International Case Series (San Diego Convention Center, Area H (Hall H, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6756;    
    Conclusion Diagnosis and management of DIPNECH is challenging due to the rarity of the condition and sparse data. We believe this to be the largest descriptive case series to date and hope this data will build our understanding of this rare disease and guide future collaborative research and care.
  • ||||||||||  Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva, Theravance Biopharma
    Rapid and Persistent 6-week Response to ICS/LABA/LAMA in Mild-moderate Asthma (San Diego Convention Center, Area F (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6700;    
    Consistent with the current result in a small group of patients, previous work provided evidence of lung function improvements at 24-weeks,3,4 in larger samples of ~2500 participants. These results in 17 patients with moderate asthma reveal that early responses at 6-weeks, persist but do not substantially improve at 12-weeks which has implications for therapy decision-making.
  • ||||||||||  sildenafil / Generic mfg.
    Swimming Induced Pulmonary Edema: A Case Report and Review of the Literature (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6348;    
    CPAP and positive expiratory pressure devices have been utilized in the prehospital setting for treatment of SIPE. NPPV is thought to work by increasing clearance of hydrostatic pulmonary edema by reducing left ventricular preload and afterload.In the future, more robust studies will be required to better understand the natural course of SIPE, find the optimal treatment, and improve prevention.
  • ||||||||||  Dip into a New Diagnosis: DIPNECH as an Uncommon Cause of Cough and Dyspnea (San Diego Convention Center, Area G (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6181;    
    Symptom management often includes inhaled corticosteroids, inhaled beta-2-agonists, antitussives, and optimization of comorbid respiratory conditions; somatostatin analogs may also be beneficial. DIPNECH is an increasingly recognized etiology of chronic cough and dyspnea and should be considered in patients for whom a clear cause of these symptoms has not been found.